Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects

Rohini Mehta1,2, Arpan Neupane1,2, Lei Wang1,2, Zachary Goodman1,3, Ancha Baranova1,2 and Zobair M Younossi1,3*

Abstract

Background: Visceral obesity is often accompanied by non-alcoholic fatty liver disease (NAFLD). Activation of NACHT, LRR and PYD domains-containing proteins (NALPs) may contribute to the release of pro-inflammatory cytokines by adipose and the obesity-associated progression of NAFLD to non-alcoholic steatohepatitis (NASH).

Methods: We analyzed visceral adipose expression of various NALPs and its downstream effectors caspase-1, ASC (Apoptosis-associated speck-like protein containing a CARD), IL-18 (Interleukin-18) and IL-1β (Interleukin-1Beta) in obese subjects (BMI ≥ 35) with biopsy proven NAFLD.

Results: In adipose samples collected from NASH and pericellular fibrosis patients cohorts, expression levels of NALPs and IL-1β were lower than that in non-NASH patients. In portal fibrosis, the levels of mRNA encoding anti-inflammatory NALP6 were upregulated. The expression levels of all NALPs were significantly co-correlated. Circulating IL-18 levels were associated with increased liver injury markers AST and ALT and portal fibrosis.

Conclusion: Our observations point at a possible shift in inflammation and fibrotic response from adipose tissue to liver and a possible negative feedback regulation of tissue inflammation that may instigate NAFLD severity.

Keywords: Obesity, NAFLD, Inflammasomes, Cytokines, Fibrosis

Background

The prevalence of obesity in United States has remained unabated over the past 10 years with ~35% prevalence among adults [1]. A pro-inflammatory state (also referred to as low-grade chronic inflammation/meta-inflammation/sterile inflammation) associated with visceral obesity, has been also shown to be strongly correlated with the development of non-alcoholic fatty liver disease (NAFLD) [2]. This non-pathogen associated pro-inflammatory state can be stimulated and propagated by a variety of damage-associated molecular patterns (DAMPs) that originate from damaged tissue and/or tissue under stress [3-5]. Once released, DAMPs bind to pattern-recognition receptors (PRRs) to elicit an immune response by promoting the release of pro-inflammatory mediators and by recruiting the immune cells to the tissue.

Among the five main classes of vertebrate PRRs, the largest receptor family is comprised by nucleotide oligomerization and binding domain (NOD)-like receptors (NLRs) with a conserved NOD motif [6]. NLRs are believed to be the most evolutionarily ancient family of PRRs [7]. NACHT, LRR and PYD domains-containing proteins (NLRPs/NALPs) belong to the NOD-like receptor (NLR) family that differs from other NLRs by their N-terminal PYD domains [8,9].

Recently NALPs have attracted attention as PRRs that link recognition of DAMPs with the regulation of inflammatory response [7,10]. Human genome encodes 14 NALPs, some of which are required for inflammasome formation [9]. The inflammasomes are large, signal-induced multiprotein complexes responsible for the proteolytic cleavage and activation of procaspases-1. In turn, activated caspase-1 promotes maturation of the pro-inflammatory cytokines interleukin-18 (IL-18), interleukin-1β (IL-1β) and
interleukin-33 (IL-33) [10,11,12]. The NALP1 inflamma-
some is composed of NALP1, apoptosis-associated speck-
like protein containing a carboxy-terminal CARD (ASC),
caspase-1, and caspase-5, whereas the NALP2/3 inflam-
masome contains NALP2 or NALP3, CARDINAL, ASC,
and caspase-1 [13].

The downstream targets of inflammasomes include
known regulators of inflammation and immunity- IL-1β
and IL-18. IL-1β triggers the production of interleukin-6
(IL-6) and tumor necrosis factor-alpha (TNF-α), two cy-
tokines that elicits immune cell migration and infiltra-
tion into tissue [14], and promote the generation and
maintenance of interferon-gamma (IFN-γ) and interleukin-
17 (IL-17) producing T cells [15]. Interleukin-18 (IL-18)
incites immune cell recruitment and activation [11] and
influences natural killer (NK) cell and T cell effector re-
sponses [16,17].

A large number of recent studies have shown adipose
tissue to be the major source of inflammatory molecules
in obesity [18-21]. The expression patterns of NALPs
have not been previously explored in visceral adipose. It
is reasonable to speculate that NALPs may be activated
in adipose tissue of obese individuals and that these
NALPs may contribute to the release of pro-inflammatory
IL-1β and IL-18 from adipocytes, the development of the
systemic inflammation and the obesity-associated progres-
sion of non-alcoholic fatty liver disease (NAFLD) to non-
alcoholic steatohepatitis (NASH).

With this in mind, we profiled visceral adipose expres-
sion of 14 NALPs as well as caspase-1, ASC, IL-18 and
IL-1β in 45 obese subjects (BMI ≥ 35) with biopsy proven
NAFLD. Expression levels of NALPs were correlated to
the serum indicators of system-wide inflammation IL-1β
and IL-18 and to various parameters describing the under-
lying liver pathology.

Methods

Sample collection

This study has been approved by Internal Review Board of
Inova Fairfax Hospital. After written informed consent,
omental adipose tissue and serum samples from 45 obese
patients (BMI = 47 ± 11) undergoing bariatric surgery were
collected. The samples were immediately flash frozen in li-
quid nitrogen and added to the repository of specimens
stored at −80°C. The samples were de-identified in com-
pliance with HIPAA regulations. For each patient, a liver
biopsy was also performed and subjected to histopatho-
logical evaluation. Clinical data were available for all the
samples in the repository and included pre-surgery fasting
glucose, serum aminotransferases (alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST)) and lipid
panel. None of the included subjects reported to have ex-
cessively consumed alcohol (>10 grams/day in women
and >20 grams/day in men) in the past 5 years. Other
chronic liver diseases were excluded by negative serology
for hepatitis B and C, no history of toxic exposure and no
other cause of chronic liver disease.

Pathological assessment

After staining with hematoxylin-eosin or Masson tri-
chrome, the slides were reviewed by single hepatopathol-
ogist (Z.G.) that followed a predetermined histologic
grading system [22] that included quantitative evaluation
of the fibrosis and various inflammatory features.

Definitions and scoring

Steatosis was histologically defined as the presence of >5%
hepatic fat with or without lobular inflammation and
with/without portal inflammation and graded on a scale of
0–3 as follows: 0 = none, 1 ≤ 5%, 2 = 6–33%, 3 = 34–66%,
4 = >66%. Immune cell infiltrates (lymphoplasmacytoid
cells, Kupffer cell hypertrophy and neutrophil presence)
were scored on a score of 0–3 as follows: 0 = none, 1 =
mild or few, 2 = moderate, 3 = marked or many. Lobular
inflammation was defined by sum of scores of the pres-
ence of lymphoplasmacytoid cells, Kupffer cell hyper-
trophy and neutrophil infiltration. Portal inflammation,
hepatic cell ballooning, pericellular/perisinusoidal fi-
brosis, and portal fibrosis were graded on a scale of 0 to
3: (0) none, (1) mild or few, (2) moderate, or (3) marked
or many. Advanced fibrosis was defined by a sum of
score of portal and pericellular fibrosis as being greater
or equal to 3. Bridging fibrosis was scored as (0) none,
(1) few bridges, or (2) many bridges. Cirrhosis was scored
as (0) absent, (1) incomplete, or (2) established. NASH was
histologically defined as steatosis, lobular inflammation,
and ballooning degeneration with or without Mallory Denk
bodies, and with or without pericellular fibrosis. Patients
who had hepatic steatosis (with or without lobular inflam-
mation) or NASH were considered to have NAFLD [22].

RNA extraction and reverse transcription

Total RNA was extracted from visceral adipose tissue
(100 mg) using Aurum Total RNA Fatty and Fibrous
Tissue Kit (Bio-Rad, USA) and eluted in 30 μL of RNase
free water (Fisher Scientific, USA). The quantity and
purity of the extracted RNA was determined by absorb-
ance at 260 nm (A260) and 280 nm (A280) measured by
the GeneQuant1300 spectrophotometer (GE Healthcare,
USA). A260/A280 ratio between 1.8 and 2.1 was consid-
ered as an indicator of high quality RNA. The integrity
of total RNA was verified by 1% agarose gel electrophor-
esis with ethidium bromide (10 μg/ml). The results were
documented using Molecular Imager (Bio-Rad, USA).
All total RNA samples demonstrated a 2:1 intensity ratio
of sharp, clear 28S and 18S rRNA bands.

To prevent deterioration of RNA during storage,
cDNA synthesis was carried out on the same day as total
RNA extraction using RT² HT First Strand Kit (Qiagen). According to manufacturer's protocol, 1 μg of total RNA was subjected to a genomic DNA elimination step prior to reverse transcription. Reverse transcription was carried out in the presence of random hexamers and oligo-dT and resultant cDNA preps were diluted to a final volume of 111 μL.

Quantitative RT-PCR
Validated primers for specific amplification of NALP1-NALP14, Caspase-1, ASC, IL-1B and IL-18 mRNA were as described in relevant publications (see Additional file 1: Table S1). The specificity of each primer was verified using NCBI BLAST [23] and the correct size of PCR product was confirmed by gel electrophoresis in 2% agarose. For the purpose of normalization, visceral adipose validated housekeeping gene ACTB was used as the reference [24].

Quantitative real-time PCR was performed in a 96 well format in the Bio-Rad CFX96 Real Time System (BioRad, USA). The real-time PCR mixture consisted of 1 μL cDNA corresponding to 1 μg of total RNA, 250 nM primers and 1 Sso Fast Evagreen Supermix (BioRad, USA) in a final volume of 10 μL. Each plate included no template control to detect reagent contamination. Each run also included wells with TATA box binding protein (TBP) primer pair (Invitrogen, USA) and universal cDNA (Qiagen, USA) as both an interplate control and a positive control. The thermal profile of the RT-PCR procedure repeated for 50 cycles was: 1) 95°C for 30s; 2) 5 s denaturation at 95°C, 5 s annealing at 60°C (amplification data collected at the end of each amplification step); 3) dissociation curve consisting of 10 s incubation at 95°C, 5 s incubation at 65°C, a ramp up to 95°C (Bio-rad CFX96 Real Time System, USA). Melting curves were used to validate product specificity. All samples were amplified in triplicates from the same total RNA preparation and the mean value was used for further analysis. Ct values of target genes greater than 37 were considered to be a negative call and assigned a value = 37 for the purpose of normalization. Ct values of control wells (no-template control, positive control) were examined for each plate.

ELISA
Serum IL-18 levels were measured by Human IL-18 ELISA kit (R&D systems, USA) according to manufacturer's instructions. The limits of detection of the assay were at 12.5 pg/mL. Active serum IL-1β levels were measured using Quantikine HS Human IL-1β immunoassay (R&D systems, USA) according to manufacturer's instructions. The sensitivity ranges from 0.023 pg/mL to 0.14 pg/mL. The limits of detection in this assay was at 0.125 pg/mL.

Data analysis
Among samples that differed in their histologically determined severity scores, group comparisons (Table 1) were performed using non-parametric Mann Whitney U test. Spearman’s correlation analysis was carried out. In all cases, the p- values of < 0.05 were considered to be significant.

Results
NALP4 and IL-1B encoding mRNAs are downregulated in visceral adipose of patients with pericellular fibrosis
Pericellular fibrosis scores were positively correlated with both the scores for portal fibrosis (r = 0.5321; p = 0.0003) and the degree of hepatic steatosis (r = 0.3393; p = 0.03001).

Table 1 Demographic and clinical characteristics of patient cohorts profiled for expression of NALPs and other inflammasome components and targets

| Demographic or clinical parameter (N = 45) | Average SD or percentage |
|------------------------------------------|--------------------------|
| Clinical & Demographic Data              |                          |
| BMI                                      | 47.4 10.8                |
| Age                                      | 42.7 11.9                |
| Gender (Females)                         | 62.2%                    |
| Triglyceride (mg/dL)                     | 158.3 96.7               |
| AST (U/L)                                | 27.7 18.8                |
| ALT (U/L)                                | 36.7 29.3                |
| Glucose (mg/dL)                          | 106.4 32.2               |
| Diabetes (Presence)                      | 57.7%                    |
| Liver Histological Data                  |                          |
| Non-NASH NAFLD                          | 55.5%                    |
| NASH (Presence)                          | 44.4%                    |
| Ballooning Degeneration (Presence)        | 28.8%                    |
| Mallory-Denk Bodies (Presence)            | 11.1%                    |
| Portal Inflammation (Presence)           | 66.6%                    |
| Advanced Lobular Inflammation (Score ≥ 3)| 28.8%                    |
| Pericellular Fibrosis (Presence)          | 44.4%                    |
| Portal Fibrosis (Presence)               | 75.5%                    |
| Advanced Fibrosis (Score ≥ 3)            | 31.1%                    |
| Focal Necrosis (Presence)                | 31.1%                    |

Steatosis is histologically defined by the presence of ≥5% hepatic fat with/without lobular inflammation and with/without portal inflammation. The degree of lobular inflammation is defined by the sum of the scores for the presence of lymphoplasmacytic cells, Kupffer cell hypertrophy and neutrophil infiltration. NASH is histologically defined by the presence of steatosis along with lobular inflammation, with/without ballooning degeneration and/or Mallory-Denk bodies and/or pericellular fibrosis. Lymphoplasmacytic cells, Kupffer cell hypertrophy and neutrophil infiltration was each scored on a scale of 0: 0 = none, 1 = mild or few, 2 = moderate, 3 = marked or many. Portal inflammation, hepatocellular ballooning, pericellular/perisinusoidal fibrosis, and portal fibrosis were graded on a scale of 0 to 3: (0) none, (1) mild or few, (2) moderate, or (3) marked or many. Advanced fibrosis was defined by a sum of score of portal and pericellular fibrosis as being greater or equal to 3. Bridging fibrosis was scored as (0) none, (1) few bridges, or (2) many bridges. Cirrhosis was scored as (0) absent, (1) incomplete, or (2) established [22].
In visceral adipose of patients with pericellular fibrosis, the levels of NALP4-encoding mRNA were significantly lower than that in the cohort without the pericellular fibrosis (0.18 \( \pm \) 0.20 vs 1.12 \( \pm \) 2.53; \( p < 0.019 \)) (Table 2). The levels of mRNA for an inflammatory cytokine IL-1B were also significantly lower in the group with pericellular fibrosis (6.17 \( \pm \) 12.05 vs 14.96 \( \pm \) 18.21; \( p < 0.003 \)) (Table 2). Accordingly, adipose specific expression levels of NALP4 and IL1B mRNAs negatively correlated with pericellular fibrosis (\( r = -0.33 \); \( p < 0.037 \) and \( r = 0.47 \); \( p = 0.002 \), respectively), while circulating levels of IL-18 cytokine were positively correlated with the scores for this histopathological feature (\( r = 0.3365 \); \( p < 0.04 \)).

NALP6 encoding mRNA and serum levels of IL-18 are upregulated in portal fibrosis

Expression levels of NALP6 mRNA were significantly higher in visceral adipose of patients with portal fibrosis as compared to that of the patients with no evidence of portal fibrosis (0.86 \( \pm \) 0.93 vs 0.38 \( \pm \) 0.38; \( p = 0.028 \)) (Table 2). Interestingly, circulating levels of IL-18, an inflammatory cytokine that functions downstream of inflammasome, were significantly higher in patients with portal fibrosis (390.95 pg/mL \( \pm \) 176.84 pg/mL vs 246.08 pg/mL \( \pm \) 103.10 pg/mL; \( p = 0.022 \)) (Table 2). Accordingly, circulating levels of IL-18 were also positively correlated with the scores for portal fibrosis (\( r = 0.4226 \); \( p < 0.01 \)).

Adipose inflammasome signature associated with inflammatory features and NASH

Among the genes assessed for expression, NALP 4, 5, 7, 8, 9, 10, 11, 13 and IL-1B were significantly downregulated in adipose tissue samples collected from NASH cohort (Table 2).

| Table 2 | Significantly altered targets in analyzed cohorts |
|---------|--------------------------------------------------|
| AST (U/L) | Pericellular fibrosis presence (N = 20) | Pericellular fibrosis absence (N = 25) | P value |
| Males | 34.75 \( \pm \) 25.06 | 22.62 \( \pm \) 9.19 | 0.023 |
| Females | 50.0% | 19.0% | 0.036 |
| Advanced fibrosis presence (Score \( \geq \) 3) | 35.7% | 25% | NS |
| NALP4 mRNA | 0.18 \( \pm \) 0.20 | 1.12 \( \pm \) 2.53 | 0.019 |
| IL1B mRNA | 6.17 \( \pm \) 12.05 | 14.96 \( \pm \) 18.21 | 0.003 |
| Portal fibrosis presence (N = 34) | Portal fibrosis absence (N = 11) | P value |
| Advanced fibrosis presence (Score \( \geq \) 3) | 45.2% | 0 | 0.008 |
| NASH | 58.1% | 20% | 0.03 |
| NALP6 mRNA | 0.86 \( \pm \) 0.93 | 0.38 \( \pm \) 0.38 | 0.028 |
| IL-18 (pg/mL) | 390.95 pg/mL \( \pm \) 176.84 | 246.08 pg/mL \( \pm \) 103.10 | 0.022 |
| NASH (N = 20) | Non-NASH NAFLD (N = 25) | P value |
| Gender (Females) | 50% | 81% | < 0.036 |
| Portal Fibrosis (presence) | 1.35 \( \pm \) 0.67 | 0.71 \( \pm \) 0.64 | < 0.005 |
| Pericellular Fibrosis (presence) | 1.45 \( \pm \) 0.60 | 0.05 \( \pm \) 0.22 | < 0.001 |
| Advanced fibrosis (Score \( \geq \) 3) | 60% | 9.5% | < 0.0006 |
| Degree of lobular inflammation | 2.55 \( \pm \) 1.61 | 1.52 \( \pm \) 0.98 | < 0.02 |
| AST (U/L) | 35.70 \( \pm \) 24.79 | 21.71 \( \pm \) 8.52 | < 0.004 |
| NALP 4 mRNA | 0.16 \( \pm \) 0.19 | 1.14 \( \pm \) 2.53 | < 0.002 |
| NALP 5 mRNA | 0.14 \( \pm \) 0.12 | 1.24 \( \pm \) 2.58 | < 0.02 |
| NALP 7 mRNA | 0.14 \( \pm \) 0.12 | 1.09 \( \pm \) 2.54 | < 0.03 |
| NALP 8 mRNA | 0.14 \( \pm \) 0.12 | 1.09 \( \pm \) 2.54 | < 0.03 |
| NALP 9 mRNA | 0.14 \( \pm \) 0.12 | 1.25 \( \pm \) 2.70 | < 0.03 |
| NALP 10 mRNA | 0.14 \( \pm \) 0.12 | 1.09 \( \pm \) 2.54 | < 0.03 |
| NALP 11 mRNA | 0.14 \( \pm \) 0.12 | 1.09 \( \pm \) 2.54 | < 0.03 |
| NALP 13 mRNA | 0.14 \( \pm \) 0.12 | 1.09 \( \pm \) 2.54 | < 0.03 |
| IL-1B mRNA | 8.71 \( \pm \) 15.45 | 12.66 \( \pm \) 16.68 | < 0.02 |
scores \((r = 0.3713; \ p = 0.016\) and the histopathologically determined Kupffer cell hypertrophy \((r = 0.41; \ p = 0.006\). Additionally, expression levels of NALP3 mRNA in adipose were positively correlated with serum levels of liver enzyme AST \((r = 0.32; \ p = 0.03\).

**Inflammasome components are co-regulated in adipose**

The pattern of the correlation between expression levels for mRNAs encoding inflammasome components and its downstream targets (NALP1-14, ASC, CASP-1, IL-1B and IL-18 mRNA) shows that these genes are co-regulated in adipose tissue (Table 3). In our study, expression levels of NALP1 mRNA positively correlated with that of NALP4 \((r = 0.3984; \ p = 0.01\), NALP11 \((r = 0.3294; \ p = 0.04\) and NALP14 \((r = 0.4134; \ p = 0.008\). Expression levels of NALP2 mRNAs were positively correlated with that of all the other non-inflammasome forming NALP members (NALP4 - NALP14) as well as with levels of IL-18 mRNA \((r = 0.5241; \ p < 0.001\). The expression levels of NALP3 mRNA were correlated with that of NALP5 \((r = 0.3188; \ p = 0.04\), NALP12 \((r = 0.3662; \ p = 0.02\), NALP14 \((r = 0.3484; \ p = 0.027\) as well as ASC \((r = 0.78; \ p < 0.0001\) and CASP-1 \((r = 0.389; \ p = 0.012\). The levels of NALP4 mRNA were co-correlated with levels of NALP5, NALP7-14 and IL-18 mRNA (Table 3), while levels of NALP5 mRNA were co-correlated with NALP7-14 and IL-18 mRNAs (Table 3). NALP6 mRNA levels were co-correlated with that of NALP12 \((r = 0.3227; \ p = 0.048\). The levels mRNAs for NALP7, NALP8, NALP9 and NALP10 were co-correlated with NALP11, NALP12, NALP14 and IL-18 mRNA (Table 3). The levels of NALP11 mRNA were co-correlated with NALP12/13/14 and IL-18 mRNA, the levels of NALP12 co-correlated with NALP13, NALP14, ASC and IL-18 mRNA, and the levels of NALP13 co-correlated with NALP14 and IL-18 mRNA. The levels of NALP14 were co-correlated with that of IL-18 mRNA, while the levels of ASC were co-correlated with that of CASP-1 and IL-1B mRNAs.

**Discussion**

Systemic inflammation is a common finding in both visceral obesity and chronic liver disease [25,26]. Inflammasome activation has been recently recognized to play an increasingly important role in the development of liver disease [27-29]. However, the tissue source and mechanisms of inflammasome mediated liver damage in obesity associated NAFLD remain disputed [29,30]. Activation of inflammasomes involves two separate steps, the priming of tissue to inflammatory response that results in transcriptional activation of NALPs, IL18 and IL1B genes, and the activation of the inflammasome complex that culminates in the secretion of active pro-inflammatory IL-1\(\beta\) and IL-18 cytokines. To better understand the role of adipose specific inflammasome components in NAFLD, we assessed the adipose tissue mRNA for inflammasome components and serum levels of its downstream targets in 45 morbidly obese patients (BMI \(\geq 35\)) with various liver conditions of NAFLD spectrum.

Previous studies have shown that the NALP3 inflammasome and NALP3-dependent caspase-1 activation are central to the inflammation and the development of the liver fibrosis [31]. In our study, expression levels of NALP3 mRNA in adipose were positively correlated with serum levels of liver enzyme AST \((r = 0.32; \ p = 0.03\) and the levels of mRNA encoding caspase-1 were positively correlated with Kupffer cell hypertrophy and the hepatic lobular inflammation scores. However, to our surprise, the levels of mRNA encoding for NALP 4, 5, 7, 8, 9, 10, 11, 13 and IL-1B were significantly downregulated in adipose tissue samples collected from NASH cohort as compared to patients without NASH (Table 2). Moreover, the expression patterns of mRNA for many NALPs, especially for non-inflammasome forming NALPs, were co-correlated to each other (Table 3).

So far, only NALPs 1 3 have been shown to form active inflammasome, while the functions of other NALPs remain obscure [9]. Some NALP proteins, for example, NALP12 and NALP6, have been previously shown to suppress inflammation through down regulation of NF-κB signaling subsequent to TLR activation [3]. Another revolving theme in the study of non-classic NALPs, for example, NALP5, NALP7, NALP8 and NALP9 is their involvement in oocyte maturation, implantation and other fertility-related processes [32,33]. It is tempting to speculate that the decrease in adipocytic expression of these NALPs may contribute to decreased fertility in patients with NASH and metabolic syndrome, possibly through known association of NASH with polycystic ovary syndrome (PCOS) [34,35]. Non-inflammasome related NALPs may also play as yet unknown roles in pathogenesis of obesity-associated disorders through modulation of adipocytic secretion or other pathways.

Interestingly, mRNAs encoding for NALP4 and its substrate IL1B were both downregulated in the cohort with hepatic pericellular fibrosis, while recently published study of Boaru et al. showed time and concentration-dependent increase in expression of NALP4 in cultured hepatic stellate cells upon lipopolysaccharide (LPS) stimulation [29]. This would suggest a role for NALP4 in promoting fibrotic response by activated stellate cells. The contradiction between our data and observation of Boaru et al. [29] may be attributed to either yet unknown tissue specific differences in the function of NALP4, or to a negative feedback signal operating between adipose tissue and liver which may be, in fact, time dependent. It is possible that the inflammation and the fibrotic processes may be initiated in adipose tissue as described Reggio et al., [36], but later be shifted to distant organs such as liver. This
Table 3 Correlation among mRNA expression levels of inflammasome components

| Rho (p-value) | NALP1 | NALP2 | NALP3 | NALP4 | NALP5 | NALP6 | NALP7 | NALP8 | NALP9 | NALP10 | NALP11 | NALP12 | NALP13 | NALP14 | IL18 | ASC | CASP1 | IL1B |
|---------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|------|-----|-------|------|
| NALP1         | -     | -     | -     | 0.3984 (0.01) | -     | -     | -     | -     | -     | -     | -     | 0.3294 (0.04) | -     | -     | 0.4134 (0.008) | -     | -     | -     |
| NALP2         | -     | -     | -     | 0.5336 (<0.001) | 0.5068 (<0.001) | 0.394 (0.01) | 0.5274 (<0.001) | 0.5274 (<0.001) | 0.5274 (<0.001) | 0.5096 (<0.001) | 0.5231 (<0.001) | 0.5274 (<0.001) | 0.4799 (0.001) | -     | -     | -     | -     |
| NALP3         | -     | -     | -     | -     | 0.3188 (0.044) | -     | -     | -     | -     | -     | -     | 0.3662 (0.02) | -     | 0.3484 (0.027) | -     | 0.7826 (<0.001) | 0.389 (0.012) | -     |
| NALP4         | -     | -     | -     | -     | -     | 0.8199 (<0.0001) | -     | 0.8375 (<0.0001) | 0.8375 (<0.0001) | 0.8375 (<0.0001) | 0.8768 (<0.0001) | 0.6051 (<0.0001) | 0.8375 (<0.0001) | 0.8317 (<0.0001) | 0.3937 (0.01) | -     | -     |
| NALP5         | -     | -     | -     | -     | -     | -     | 0.9856 (<0.0001) | 0.9856 (<0.0001) | 0.9856 (<0.0001) | 0.9768 (<0.0001) | 0.7439 (<0.0001) | 0.9856 (<0.0001) | 0.8829 (<0.0001) | 0.564 | -     | -     | -     |
| NALP6         | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.3227 | -     | -     | -     | -     | -     | -     |
| NALP7         | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.9931 (<0.0001) | 0.7672 (<0.0001) | -     | 0.9023 (<0.0001) | 0.5581 (<0.0001) | -     | -     | -     |
| NALP8         | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.9931 (<0.0001) | 0.7672 (<0.0001) | -     | 0.9023 (<0.0001) | 0.5581 (<0.0001) | -     | -     | -     |
| NALP9         | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.9931 (<0.0001) | 0.7672 (<0.0001) | -     | 0.9023 (<0.0001) | 0.5581 (<0.0001) | -     | -     | -     |
| NALP10        | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.9931 (<0.0001) | 0.7672 (<0.0001) | -     | 0.9023 (<0.0001) | 0.5581 (<0.0001) | -     | -     | -     |
| NALP11        | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.758 (<0.0001) | 0.9931 (<0.0001) | 0.9212 (<0.0001) | 0.5478 (<0.0001) | -     | -     | -     |
| NALP12        | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.7672 (<0.0001) | 0.8427 (<0.0001) | 0.514 (<0.001) | 0.3657 (0.02) | -     | -     | -     |
| NALP13        | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.9023 (<0.0001) | 0.5581 (<0.0001) | -     | -     | -     | -     | -     |
| NALP14        | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.5751 (0.001) | -     | -     | -     | -     |
| IL18          | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | 0.3931 (0.001) |
| ASC           | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     |
| CASP          | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     |
| IL1B          | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     |
may be accompanied with negative feedback signaling that originates in the liver and attempts to restore homeostasis. The observed downregulation of adipose-specific production of IL1B mRNA in patients with pericellular fibrosis (Table 2 and Figure 1) as well as NASH (Table 2 and Figure 2) also supports this hypothesis. The downregulation at expression level is also supported by the lack of detectable IL1B protein levels in circulation (Assay Range: 0.125 - 8 pg/mL). Unlike the production of most inflammatory cytokines, the production of biologically active IL-1β is dependent on transcription, translation, maturation and secretion mechanisms, all of which are tightly regulated in tissue-specific manner. This may be attributed to tissue specific roles of IL1B. Animal studies showed that hepatic IL-1β protein and mRNA levels to be increased in various diet-induced NASH models in mice [28], while adipose specific IL1B deficiency in mice increase susceptibility to obesity [28,37]. In another recent study, the authors demonstrate in animal models that IL-1β supports ectopic fat accumulation in hepatocytes and adipose-tissue macrophages, contributing to impaired fat-liver crosstalk in nutritional obesity [38]. While the translation of animal studies to humans is difficult, the discrepancy in observed expression levels of IL1B in obesity associated NASH and pericellular fibrosis maybe attributed to the extremely high BMI of the cohort being examined (BMI ≥ 35). This along with the observed negative correlation of IL1B mRNA levels with BMI (r = 0.317; p = 0.04) indicates an ongoing negative feedback loop between adipose specific IL1B expression and an accumulation of VAT.

Further support to the hypothesis centering on ongoing negative feedback loop operating between adipose tissue and liver in morbidly obese individuals with severe NAFLD, is provided by result of the comparison in another cohort. In cohort of subjects with portal fibrosis compared to those without portal fibrosis, adipose specific NALP6 mRNA (Table 2 and Figure 3) and circulating IL18 (Table 2 and Figure 3) protein were upregulated with hepatic portal fibrosis, while adipose specific IL18 mRNA was not significantly different in the same cohort. This is interesting, since NALP6 has been shown to have an anti-inflammatory role by downregulating NF-kB signaling subsequent to TLR activation [3]. Conspicuously, whilst circulating IL-18 protein was upregulated in portal fibrosis (Table 2 and Figure 3), this was not accompanied with an upregulation of adipose specific IL18 mRNA. Additionally, circulating IL-18 was found to be positively correlated with BMI (r = 0.41; p = 0.012). This is in agreement with previous studies [39-43]. Notably, circulating IL-18 levels are also associated with increased liver injury markers [44]: AST (r = 0.33; p = 0.04) and ALT (r = 0.41; p = 0.01) levels respectively as seen in previous reports [43]. Since IL-18 is more widely expressed, this may indicate additional sources of circulating IL-18 protein such as from the gut [28] or the liver [45], playing a role in the inflammation and hepatic injury progression. Thus, IL-18 might contribute to the development of liver disease, albeit the origin of IL-18 may not be solely from adipose.

For the first time, we profiled gene expression profile of all the 14 members of NALPs in visceral adipose tissue. As can be seen from correlation analysis (Table 3), the expression of these genes is significantly correlated with each other. While most of the studies on obesity and insulin resistance have focused on NALP3 mediated inflammasome, our study showed that there is a need for exploring roles of other members of this family of proteins in systemic inflammation and chronic liver conditions.

Among the limitations of this study is that the gene expression analysis has been carried out in whole

---

**Figure 1** Significantly altered gene expression in presence of pericellular fibrosis vs absence of pericellular fibrosis. A.) NALP4 gene expression; B.) IL1B gene expression.
adipose tissue instead of studying isolated tissue components, i.e. adipocytes and stromal vascular cells. This study was limited to two markers of systemic inflammation, IL1B and IL18 that were selected as known targets released into circulation upon activation. The profiling of greater variety of inflammatory molecules may yield better mechanistic resolution of inflammatory responses in adipose. Another avenue to explore is the parallel study of NALP component expression in liver and other peripheral tissues, and the study of NALP components at protein level.

**Conclusion**

The results of our study indicate that non-inflammasome related NALPs may play as yet unknown roles in pathogenesis of obesity-associated disorders through modulation of adipocytic secretion or other pathways. Our observations also point at a possible shift in inflammation and fibrotic response from adipose tissue to liver in patients with severe obesity. While this hypothesis needs further experimental verification, it takes us a step closer in understanding the underlying reason for some obese individuals being metabolically healthy as compared to...
metabolically unhealthy obese. Additional study of matched liver and adipose tissues from same individuals will help delineate the cross talk mechanisms between inflammation and fibrosis in obesity and NAFLD.

Additional file

Additional file 1: Table S1. A list of validated primers.

Abbreviations

NAFLD: Non-alcoholic fatty liver disease; NALPs: NACHT, LRR and PYD domains-containing proteins; NASH: Non-alcoholic steatohepatitis; ASC: Apoptosis-associated speck-like protein containing a CARD; IL-18: Interleukin-18; IL-1β: Interleukin-1 Beta; BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; DAMPs: Damage-associated molecular patterns; PRRs: Pattern-recognition receptors; NLRS: Nucleotide oligomerization and binding domain NOD-like receptors; IL-33: Interleukin-33; TNF-α: Tumor necrosis factor-alpha; IFN-γ: Interferon-gamma; IL-17: Interleukin-17; PCOS: Polycystic ovary syndrome.

Competing interests

The authors declare that they have no competing interests.

Authors contributions

RM conceived and designed the study, carried out the ELISA and qRT-PCR studies, provided daily supervision for AN, a MS student and drafted the manuscript. AN validated the primers and assisted in qRT-PCR studies. LW carried out statistical analysis of data. ZG provided the histopathological assessment of liver biopsies. AB participated in its design and finalized the manuscript. ZM participated in the design of the study. All authors read and approved the final manuscript.

Acknowledgements

This work has been performed at the Translational Research Institute, as part of the collaborative effort between George Mason University and Inova George Mason and Fairfax Hospital. We would like to thank both our Inova and George Mason teams for their invaluable help and assistance. This study was funded by an Internal Seed grant from Inova Health System.

Author details

1. Betty and Guy Beatty Obesity and Liver Program, Inova Health System, Falls Church, VA, USA.
2. Center for the Study of Chronic Metabolic Diseases, School of Systems Biology, College of Science, George Mason University, Fairfax, VA, USA.

Received: 13 August 2014 Accepted: 27 November 2014

Published online: 16 December 2014

References

1. Flegal KM, Caroll MD: Prevalence of obesity and trends in the distribution of body mass index among us adults, 1999 2010. JAMA 2012, 307:491-497.
2. Kubo P, Mehali WZ: Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1172.
3. Kono H, Rock KL: How dying cells alert the immune system to danger. Nat Rev Immunol 2008, 8:279-289.
4. Rock KL, Latz E, CintiVrors F, Kono H: The sterile inflammatory response. Annu Rev Immunol 2010, 28:321-342.
5. Maslanka T, Mahaffey LF, Tamnura K, Bininsson L, Greenwood BN, Fleshner M: The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav Immun 2013, 28:54-62.
6. Wilmanski JM, Petnicke-Ocwiage T, Kobayashi KS: NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. J Leukoc Biol 2008, 83:13-30.
7. Lupfer C, Kanneganti TD: The expanding role of NLRs in antiviral immunity. Immunol Rev 2013, 255:13-24.
8. Martinon F, Gade O, Ptrlivl V, Mayor A, Tschopp J: NALP inflammasomes: a central role in innate immunity. Semin Immunopathol 2007, 29:213-229.
9. Tschopp J, Martinon F, Burns K: NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003, 4:95-104.
10. Bryan NB, Dorleefruter A, Rojanakul Y, Stelik C: Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain. J Immunol 2009, 182:3173-3182.
11. Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998, 16:457-499.
12. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro-IL-beta. Mol Cell 2002, 10:417-426.
13. Martinon F, Tschopp J: Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2006, 14:10-22.
14. Sims JE, Smith DE: The IL-1 family: regulators of immunity. Nat Rev Immunol 2011, 11:89-102.
15. Ben-Sasson SZ, Hogg A, Eli-Sty Y, Slukas K, Younoszi A, King S, Randhawa M, Puslulay S, Ashkedi T, Ong JP, Martin LM, Chadhoke V, Younoszi ZM: Obesity-related differential gene expression in the visceral adipose tissue. Obes Surg 2005, 15:738-765.
16. Lago F, Dieguez C, Gine-Reino J, Guisioo D: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007, 3:716-724.
17. Powell K: Obesity: the two faces of fat. Nature 2007, 447:525-527.
18. Gerner RR, Wieser V, Moschen AR, Tilg H: Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Curr J Physiol Pharmacol 2013, 91:867-872.
19. Younoszi ZM, Stepanova M, Raffa N, Makhlof F, Younoszi A, Zagrwal A, Goodman Z: Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53:1874-1882.
20. Ye J, Coulouris G, Zarekataki I, Cutucutache I, Roven S, Madderr TL: Primer-BLAST, a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012, 13:134.
21. Mehta R, Bierdeing A, Hossan A, Andey A, Chadhoke V, Younoszi Z, Baranova A: Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. BMC Mol Biol 2010, 11:39.
22. Bong AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Cire Res 2005, 96:939-949.
23. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
24. Benetti E, Chiaze F, Patel NS, Collino M: The NLRP3 inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediat Inflamm 2013, 2013:687627.
25. Szabo G, Czak T: Inflammations in liver diseases. J Hepatol 2012, 57:542-554.
26. Boan SG, Bokham-Kamphorst E, Thaa L, Haas U, Weikirkens R: Expression analysis of inflammasome in experimental models of inflammatory and fibrotic liver disease. J Inflamm 2012, 9:49.
27. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehali WZ, Strowig T, Thaiss CA, Kau AE, Eisenbarth SC, Jurczak MJ, Camporez J-P, Shulman GI, Gordon JI, Hoffman HM, Flavell RA: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
28. Wree A, Eguchi A, McGougan MD, Pensa CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE: NLRP3 inflammasome activation results in hepatic pyroptosis, liver inflammation and fibrosis. Hepatology 2014, 59(3):989-910.
29. Ponsikasli S, Brunner RM, Galdmmer T, Kha C, Walz C, Chomdey S, Tesfay D, Schellander K, Wimmers K, Schwerin M, Bovine NALPS, NALPB, and...
NALP9 genes: assignment to a QTL region and the expression in adult tissues, oocytes, and preimplantation embryos. *Biol Reprod* 2006, 74:577–584.

33. Zhang P, Dixon M, Zucchelli M, Hambiliki F, Levkov I, Hovatta O, Kere J: Expression analysis of the NLRP gene family suggests a role in human preimplantation development. *PLoS ONE* 2008, 3:7123.

34. Baranova A, Tran TP, Afendy A, Wang L, Shamsaddini A, Mehta R, Chandhoke V, Birerdinc A, Younossi ZM: Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). *J Transl Med* 2013, 11:133.

35. Baranova A, Tran TP, Birerdinc A, Younossi ZM: Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2011, 33:801–814.

36. Reggio S, Pellegrinelli V, Climent K, Tordjman J: Fibrosis as a cause or a consequence of white adipose tissue inflammation in obesity. *Curr Obes Rep* 2013, 2:1–9.

37. Garcia MC, Wernstedt I, Berndtsson A, Enge M, Bell M, Hultgren O, Horn M, Ahm B, Enerback S, Ohlsson V, Jansson J-O: Mature-onset obesity in interleukin-1 receptor I knockout mice. *Diabetes* 2006, 55:1205–1213.

38. Kotas ME, Jurczak MJ, Annicelli C, Gillum MP, Cline GW, Shulman GI, Medzhitov R: Role of caspase-1 in regulation of triglyceride metabolism. *PNAS* 2013, 110:4810–4815.

39. Nov O, Shapiro H, Pavlovitch T, Dvir I, Shemesh E, Kovsan J, Shelef I, Carmi Y, Voronov E, Apte RN, Lewis E, Haim Y, Konrad D, Bashan N, Rudich A: Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. *PLoS ONE* 2013, 8:e53626.

40. Bruun JM, Stallknecht B, Helge JW, Richelsen B: Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. *Eur J Endocrinol* 2007, 157:465–471.

41. Esposito K, Pontillo A, Ciattola M, Di Palo C, Grella E, Nicoletti G, Giugliano D: Weight loss reduces interleukin-18 levels in obese women. *J Clin Endocrinol Metab* 2002, 87:3864–3866.

42. Membrez M, Ammon-Zufferey C, Philippe D, Aprikian O, Monnard I, Mac K, Darimont C: Interleukin-18 protein level is upregulated in adipose tissue of obese mice. *Obesity* 2009, 17:393–395.

43. Wang H-N, Wang Y-R, Liu G-Q, Liu Z, Wu P-X, Wei X-L, Hong T-P: Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. *World J Gastroenterol* 2008, 14:7240–7246.

44. Paschos P, Paletas K: Non alcoholic fatty liver disease and metabolic syndrome. *Hippokratia* 2009, 13:9–19.

45. Finotto S, Siebler J, Hausding M, Schipp M, Wetz S, Klein S, Protschka M, Doganci A, Lehr HA, Trautwein C, Khosravi-Far R, Strand D, Lohe A, Gale PB, Blessing M, Neurath MF, Khosravi-Fahr R: Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. *Gut* 2004, 53:392–400.

doi:10.1186/s12876-014-0208-8

Cite this article as: Mehta et al.: Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. *BMC Gastroenterology* 2014 14:208.